– President Donald Trump’s administration launched ‘TrumpRx’ on February 5th, a platform designed to offer Americans lower prescription drug prices, and the move is already sending ripples through the healthcare industry.
Trump Rx Aims to Disrupt Drug Pricing
The new government platform promises to deliver medications at prices comparable to those paid in other developed nations, potentially upending the power of pharmacy benefit managers (PBMs).
- The launch of TrumpRx could significantly reduce the influence of PBMs, often called the “invisible hand” in U.S. healthcare.
- Novo Nordisk’s Wegovy and Ozempic are now available through the platform at discounts of 70 to 80 percent.
- The Federal Trade Commission’s 2024-2025 market report revealed the ‘Big 3’ PBMs control approximately 70% of prescription drug sales.
For decades, the U.S. prescription drug market has been characterized by complex negotiations and substantial rebates, often benefiting PBMs more than consumers. These companies act as intermediaries between pharmaceutical companies and insurance providers, and critics have long argued they incentivize the prescription of higher-priced drugs. Now, that system is facing a serious challenge.
What exactly is driving these changes? The U.S. government recently decided to separate PBM compensation from drug costs within Medicare Part D, opening the door for direct-to-consumer platforms like TrumpRx to offer medications at “Most Favored Nation Prices.”
The impact was immediate. Novo Nordisk’s Wegovy and Ozempic, popular medications for obesity treatment, are now available through TrumpRx for between $199 and $350 per month – a substantial discount from the previous U.S. price range of $1,000 to $1,350.
The Power of PBMs Under Scrutiny
The top three PBMs – CVS Caremark, Express Scripts, and OptumRx – currently control an estimated 80% of the U.S. prescription market. Expanding that to the top six companies reveals a market share exceeding 90%. These companies have consolidated power through vertical integration, combining insurance and pharmacy services.
According to the U.S. Federal Trade Commission’s (FTC) 2024-2025 market report, these “Big 3” PBMs monopolized roughly 70% of total prescription drug sales by directing patients to their affiliated specialty pharmacies.
Further fueling concerns is the practice of “spread pricing,” where PBMs pay pharmacies low dispensing fees while charging insurance companies significantly higher amounts, pocketing the difference. An FTC investigation found that PBMs earned at least $7.3 billion in excess profits from certain pharmaceutical products between 2017 and 2022, adding margins of hundreds to thousands of percent.
Ripple Effects Across the Healthcare Ecosystem
These changes are expected to have a broad impact. Pharmaceutical companies, previously reliant on rebates to secure formulary placement, may now face pressure to lower list prices. Insurance companies could also see their cash flow shift, with rebates returning directly to them rather than PBMs, potentially leading to lower premiums or expanded coverage.
The U.S. pharmacy landscape could also be reshaped. Independent pharmacies, struggling with opaque PBM fees and low reimbursements, may find some relief with the implementation of “reasonable contract terms.” Stephen Anderson, CEO of the National Association of Chain Drug Stores (NACDS), hailed this as “the most important federal achievement to prevent pharmacy desertification.”
However, the PBM industry is pushing back. A spokesperson for the Pharmaceutical Benefits Management Association (PCMA) stated that weakening PBM negotiating power could allow pharmaceutical companies to raise drug prices, potentially leading to a “balloon effect” where insurance premiums increase to compensate for reduced PBM profits.
In the short term, disruption is inevitable. The U.S. Department of Labor estimates that PBMs will need to spend over $1 million on average to reorganize their IT systems in the first year alone to comply with new transparency regulations. Temporary price volatility is also anticipated during contract terminations and renegotiations.
This shift could prove particularly beneficial for Korean pharmaceutical and bio companies. Korean biosimilars, often more effective and affordable than their original counterparts, have historically faced barriers to entry due to PBM rebate practices. The 100% rebate return policy is now breaking down those barriers.
